MedTrace Logo

A Phase 2 Study of STL303 in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07606365 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-05-26

No results posted yet for this study

Summary

The purpose of this clinical research study is to look at how safe STL303 is and whether it works when given to people with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). Geographic atrophy secondary to AMD is a condition where cells in the back part of the eye slowly die, causing a blurry, or missing spot in the centre of vision.

Conditions

Interventions

DRUG

STL303

STL303 arm participants will receive a specific dose of STL303

DRUG

Placebo

Placebo arm participants will receive placebo

Sponsors & Collaborators

  • Sitala Bio LTD

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-07-31
Completion
2029-08-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Czechia
  • Poland
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07606365 on ClinicalTrials.gov